Terazosin Capsule
Product Images NDC 23155-736

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Terazosin (NDC 23155-736). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Heritage Pharmaceuticals Inc. D/b/a Avet Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (98351704 9ff8 4c54 A2c2 E2841873d658 01)

Chemical structure of terazosin hydrochloride dihydrate, the active ingredient in terazosin capsules. The structure includes a quinazoline ring system with methoxy substituents and a piperazine linked to a morpholine carbonyl group. Molecular weight is 459.93.*

FDA Label Image

Image (98351704 9ff8 4c54 A2c2 E2841873d658 02)

Data table comparing symptom scores and peak flow rate changes for terazosin versus placebo in three clinical studies with various dosages, showing mean baseline values and mean percentage changes over treatment periods. The table highlights significant improvements with terazosin doses up to 10 mg.*

FDA Label Image

Image (98351704 9ff8 4c54 A2c2 E2841873d658 03)

Figure 1 from Study 1 showing two line graphs comparing placebo and terazosin groups over 3 months. The left graph displays mean change in total symptom score from baseline, with terazosin showing greater reduction than placebo. The right graph shows mean increase in peak flow rate (mL/sec) from baseline, with terazosin demonstrating a higher increase than placebo. Sample sizes are indicated for each group at study end.*

FDA Label Image

Image (98351704 9ff8 4c54 A2c2 E2841873d658 04)

Line graph titled 'Mean Change in Total Symptom Score from Baseline' from a long-term, open-label, non-placebo controlled study (N=494). The graph shows mean symptom score changes over 30 months, with the y-axis representing mean change from baseline and the x-axis the time in months. Data points indicate decreasing symptom scores over time, with statistical significance noted at several time points compared to baseline.*

FDA Label Image

Image (98351704 9ff8 4c54 A2c2 E2841873d658 05)

Line graph showing the mean change in peak flow rate from baseline over 30 months in a long-term, open-label, non-placebo controlled study of 494 participants. The y-axis represents mean change from baseline (mL/sec) and the x-axis represents time in months. Data points show an increasing trend in peak flow rate with significant changes noted at multiple time points compared to baseline.*

FDA Label Image

Image (98351704 9ff8 4c54 A2c2 E2841873d658 06)

Table showing mean changes in systolic and diastolic blood pressure from baseline to final visit in double-blind placebo-controlled studies. Data compare placebo and terazosin groups for normotensive patients (diastolic BP ≤ 90 mmHg) and hypertensive patients (diastolic BP > 90 mmHg), with sample sizes and mean changes listed for each.*

FDA Label Image

Image (98351704 9ff8 4c54 A2c2 E2841873d658 07)

A table presenting adverse reactions during placebo-controlled trials for benign prostatic hyperplasia comparing terazosin (N=636) and placebo (N=360). The table lists body systems and associated adverse events with their respective incidence percentages for both groups, including higher rates of dizziness, asthenia, postural hypotension, and nasal congestion/rhinitis in the terazosin group.*

FDA Label Image

Image (98351704 9ff8 4c54 A2c2 E2841873d658 08)

A table presenting discontinuation rates during placebo-controlled trials of terazosin for benign prostatic hyperplasia. It lists body systems and specific adverse events, comparing the percentage of patients discontinuing terazosin (636 participants) versus placebo (360 participants) for symptoms like fever, headache, postural hypotension, dizziness, and urinary tract infection.*

FDA Label Image

Image (98351704 9ff8 4c54 A2c2 E2841873d658 09)

A data table titled 'Adverse Reactions During Placebo-Controlled Trials Hypertension' comparing the incidence of adverse reactions in body systems between terazosin (N=859) and placebo (N=506). The table lists reactions by system: Body as a Whole, Cardiovascular, Digestive, Metabolic, Musculoskeletal, Nervous, Respiratory, Special Senses, and Urogenital, with percentages for each group. Statistically significant differences at p=0.05 level are marked.*

FDA Label Image

Image (98351704 9ff8 4c54 A2c2 E2841873d658 10)

A table titled 'Discontinuation During Placebo-Controlled Trials Hypertension' comparing adverse events leading to discontinuation between terazosin (N=859) and placebo (N=506). It lists body systems such as body as a whole, cardiovascular, digestive, metabolic, nervous, respiratory, and special senses with corresponding percentage values of various symptoms for each group.*

FDA Label Image

Image (98351704 9ff8 4c54 A2c2 E2841873d658 11)

FDA Label Image

Image (98351704 9ff8 4c54 A2c2 E2841873d658 12)

FDA Label Image

1 mg (98351704 9ff8 4c54 A2c2 E2841873d658 13)

Terazosin Capsules USP 1 mg oral capsules label by Avet Pharmaceuticals Inc. The label states the product contains terazosin hydrochloride equivalent to 1 mg terazosin, dispensed in a bottle of 100 capsules for prescription use only. Storage instructions, pharmacist dispensing guidance, lot, and revision details are also included.*

FDA Label Image

2 mg (98351704 9ff8 4c54 A2c2 E2841873d658 14)

Label for Terazosin Capsules, USP 2 mg by Avet Pharmaceuticals Inc. The label states the product is for oral use, prescription only, and contains 100 capsules. It includes storage instructions to protect from light and moisture, pharmacist dispensing information, and contact details for the manufacturer. The NDC number 23155-736-01 and barcode are visible.*

FDA Label Image

5 mg (98351704 9ff8 4c54 A2c2 E2841873d658 15)

Terazosin Capsules, USP 5 mg oral capsules, label from Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. The label states the product contains terazosin hydrochloride equivalent to 5 mg terazosin per capsule, with a quantity of 100 capsules. It includes prescription-only status, storage instructions to protect from light and moisture, and distributor contact information. The label also features a barcode and the NDC number 23155-737-01.*

FDA Label Image

10 mg (98351704 9ff8 4c54 A2c2 E2841873d658 16)

Terazosin Capsules, USP 10 mg oral capsules label by Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. The label includes instructions for use, storage conditions, and cautionary statements. It also states the package contains 100 capsules and is for prescription use only. The label features the Avet Pharma logo and barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.